Spark Therapeutics Inc (ONCE) Expected to Post Earnings of -$1.10 Per Share

Wall Street analysts expect Spark Therapeutics Inc (NASDAQ:ONCE) to report earnings of ($1.10) per share for the current fiscal quarter, according to Zacks Investment Research. Five analysts have issued estimates for Spark Therapeutics’ earnings, with the lowest EPS estimate coming in at ($1.38) and the highest estimate coming in at ($0.70). Spark Therapeutics reported earnings of ($1.25) per share in the same quarter last year, which would indicate a positive year-over-year growth rate of 12%. The firm is expected to issue its next quarterly earnings report on Tuesday, May 28th.

According to Zacks, analysts expect that Spark Therapeutics will report full-year earnings of ($4.31) per share for the current year, with EPS estimates ranging from ($5.64) to ($1.69). For the next fiscal year, analysts expect that the firm will report earnings of ($4.12) per share, with EPS estimates ranging from ($5.65) to ($2.15). Zacks Investment Research’s earnings per share calculations are an average based on a survey of sell-side research analysts that follow Spark Therapeutics.

Spark Therapeutics (NASDAQ:ONCE) last posted its earnings results on Tuesday, February 19th. The biotechnology company reported ($1.75) EPS for the quarter, missing the consensus estimate of ($0.86) by ($0.89). The firm had revenue of $13.15 million during the quarter, compared to the consensus estimate of $26.76 million. Spark Therapeutics had a negative net margin of 124.33% and a negative return on equity of 16.68%. Spark Therapeutics’s revenue for the quarter was up 47.9% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($1.63) earnings per share.

Several research firms have commented on ONCE. Zacks Investment Research upgraded Spark Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Tuesday, April 30th. Barclays cut Spark Therapeutics from an “overweight” rating to an “equal weight” rating and increased their price target for the company from $74.00 to $115.00 in a research note on Monday, March 25th. William Blair cut Spark Therapeutics from an “outperform” rating to a “market perform” rating in a research note on Thursday, March 7th. Stifel Nicolaus cut Spark Therapeutics from a “buy” rating to a “hold” rating and increased their price target for the company from $65.00 to $114.50 in a research note on Wednesday, February 27th. Finally, Jefferies Financial Group cut Spark Therapeutics from a “buy” rating to a “hold” rating and increased their price target for the company from $85.00 to $114.50 in a research note on Tuesday, February 26th. Eighteen analysts have rated the stock with a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the stock. Spark Therapeutics has an average rating of “Hold” and a consensus target price of $78.45.

Spark Therapeutics stock traded up $0.78 during trading hours on Thursday, hitting $108.84. The stock had a trading volume of 322,400 shares, compared to its average volume of 1,427,111. The company has a current ratio of 5.94, a quick ratio of 5.59 and a debt-to-equity ratio of 0.18. The company has a market capitalization of $4.19 billion, a PE ratio of -51.58 and a beta of 2.48. Spark Therapeutics has a one year low of $34.53 and a one year high of $114.20.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ONCE. Pearl River Capital LLC acquired a new stake in Spark Therapeutics during the fourth quarter worth approximately $31,000. Sterling Investment Advisors Ltd. bought a new position in Spark Therapeutics in the first quarter worth approximately $68,000. Meeder Asset Management Inc. bought a new position in Spark Therapeutics in the first quarter worth approximately $121,000. Quantamental Technologies LLC bought a new position in Spark Therapeutics in the fourth quarter worth approximately $126,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in Spark Therapeutics by 16.3% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,460 shares of the biotechnology company’s stock worth $135,000 after acquiring an additional 485 shares in the last quarter.

About Spark Therapeutics

Spark Therapeutics, Inc focuses on the development of gene therapy products for patients suffering from debilitating genetic diseases. Its products include LUXTURNA (voretigene neparvovec) for the treatment of patients with confirmed biallelic RPE65 mutation-associated retinal dystrophy and viable retinal cells.

Read More: How does a reverse stock split work?

Get a free copy of the Zacks research report on Spark Therapeutics (ONCE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Spark Therapeutics (NASDAQ:ONCE)

Receive News & Ratings for Spark Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.